Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

mavacamten

Bristol Myers Squibb logo

Armed with new data, BMS plans filings for Celgene CAR-T liso-cel

Achieved a 53% complete response rate in study participants

Bristol Myers Squibb logo

BMS, Acceleron Pharma’s Reblozyl to be reviewed by FDA expert panel

Could win approval in group of rare blood cancers

- PMLiVE

Amgen raises forecasts after closing $13.4bn Otezla deal

Scope to build product further with ongoing trials in additional indications

Bristol Myers Squibb logo

BMS’ Opdivo/Yervoy combination fails to shine in melanoma

Combo therapy did not show significant benefit in key patient population

Celgene building

UPDATED: BMS completes Celgene merger after FTC okay

Approval comes over ten months after acquisition announcement

Bristol Myers Squibb logo

BMS scores FDA priority review for Opdivo/Yervoy combo in liver cancer

Possible new treatment for difficult to treat cancer type

Bristol Myers Squibb logo

BMS’ Opdivo stalls in Q3, but overall figures still top expectations

Group sales rose 6% to $6bn in the third quarter

Bristol Myers Squibb logo

BMS’ Opdivo/Yervoy combo scores in front-line lung cancer

Makes case for duo therapy in NSCLC patients

What is changing in cardiovascular disease care?

Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma

Wilmington Healthcare

- PMLiVE

BMS plugs on with Opdivo plus Yervoy in first-line NSCLC

Could be an alternative treatment option to chemotherapy

- PMLiVE

Third strike for BMS’ Opdivo in brain cancer

Despite failing first endpoint, trial is set to continue

Celgene building

BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

Currently in the middle of merger

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links